Showing results (21-30 of 123) with videos related to

Sort By:
Pageof 13
Cancer Letters|June 25, 2013
Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivoKashmira Kulkarni-Datar, Sandra Orsulic, Rosemary Foster, et al.
Scientific Reports|October 7, 2025
Immunocompetent C57BL/6 syngeneic mouse ovarian cancer models with defined genetic alterationsHasmik Agadjanian, Beth Y Karlan, Christine S Walsh, et al.
Journal of Cancer Research and Clinical Oncology|December 31, 2014
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapyAnn E Walts, John S Bomalaski, Delma Ines, et al.
Pharmacology & Therapeutics|April 14, 2023
Metabolic dependencies and targets in ovarian cancerYaqi Zhang, Yinu Wang, Guangyuan Zhao, et al.
Nature|July 5, 2005
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptorStephan Gasser, Sandra Orsulic, Eric J Brown, et al.
Gynecologic Oncology|September 15, 2010
Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cellsBarbie Taylor-Harding, Sandra Orsulic, Beth Y Karlan, et al.
The Journal of Clinical Investigation|March 17, 2025
High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancerHarun Ozturk, Fidan Seker-Polat, Neda Abbaszadeh, et al.
Journal for Immunotherapy of Cancer|October 14, 2021
Immunological configuration of ovarian carcinoma: features and impact on disease outcomeJitka Fucikova, An Coosemans, Sandra Orsulic, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2010
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cellsMichael S Goldberg, Deyin Xing, Yin Ren, et al.
Pageof 13